A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Commentary|Podcasts|September 5, 2025
Sifting Through Discordant Data From ESC 2025
Following the European Society of Cardiology Congress 2025, experts gathered to discuss key Hot Line trial data.
Advertisement
Following the European Society of Cardiology Congress 2025, experts sat down again with host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-cards), CACP, to discuss key findings from the meeting. Kaitlin Hile, PharmD, BCCP; Robert Page, PharmD, MSPH, BCPS (AQ-cards), BCGP, FAHA, FHFSA, FCCP, FASHP; and Robert DiDomenico, PharmD, FCCP, FHFSA, FACC, reviewed new data from the meeting and parsed through their lingering questions.
For more information:
Beta-Blockers After Myocardial Infarction Without Reduced Ejection Fraction (REBOOT; NCT03596385)Beta-Blockers After Myocardial Infarction in Patients Without Heart Failure (BETAMI–DANBLOCK; NCT03646357, NCT03778554)Digitoxin in Patients With Heart Failure and Reduced Ejection Fraction (DIGIT-HF)Vericiguat in Patients With Chronic Heart Failure and Reduced Ejection Fraction (VICTOR): A Double-Blind, Placebo-Controlled, Randomized, Phase 3 Trial (NCT05093933)
Advertisement
Related to this article
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Neither the lipoprotein(a) [Lp(a)]–lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
2
Fall 2026 Quiz: Test Your Pharmacy Knowledge!
3
Could Divarasib Challenge Existing KRAS G12C Inhibitors in Lung Cancer?
4
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
5